AIMC Topic: Drug Administration Schedule

Clear Filters Showing 21 to 30 of 36 articles

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.

The lancet. Gastroenterology & hepatology Jun 16, 2016
BACKGROUND: In Egypt, chronic hepatitis C virus (HCV) infection occurs in around 10% of the population (about 8 million individuals), and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and mortality. Although HCV genotype 4 constitu...
Carbamates Lactams, Macrocyclic Macrocyclic Compounds Ribavirin Sustained Virologic Response Adult Humans Genotype Male Egypt Female Liver Cirrhosis Sulfonamides Drug Therapy, Combination Aged Middle Aged Treatment Outcome Hepacivirus Aged, 80 and over Administration, Oral Hepatitis C, Chronic Adolescent Young Adult Follow-Up Studies Proline Valine Antiviral Agents Cyclopropanes Drug Administration Schedule Ritonavir Anilides
View on PubMed DOI

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.

The lancet. Gastroenterology & hepatology Jun 16, 2016
BACKGROUND: Hepatitis C virus (HCV) genotype 4 infection is most commonly reported in sub-Saharan Africa and the Middle East; however, prevalence is increasing worldwide through immigration. HCV genotype 4 accounts for 20% of all infections, but clin...
Drug Administration Schedule Anilides Carbamates Lactams, Macrocyclic Adult Macrocyclic Compounds Male Middle Aged Ribavirin Adolescent Humans Sustained Virologic Response Antiviral Agents Female Genotype Aged Proline Treatment Outcome Aged, 80 and over Ritonavir Follow-Up Studies Young Adult Drug Therapy, Combination Cyclopropanes Hepatitis C, Chronic Sulfonamides Valine Hepacivirus
View on PubMed DOI

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Clinical genitourinary cancer Dec 17, 2015
INTRODUCTION: We evaluated the incidence and predictors of the use of long-term (2-3 years) versus shorter term androgen deprivation therapy (ADT) in radiation-managed men with high-risk prostate cancer.
Humans Male Treatment Outcome Androgen Antagonists Practice Patterns, Physicians' Drug Administration Schedule Regression Analysis Prostatic Neoplasms Prostate-Specific Antigen Neoplasm Grading Tertiary Care Centers
View on PubMed DOI

Differential testosterone response to GnRH-induced LH release before and after musth in adult Asian elephant (Elephas maximus) bulls.

Theriogenology Dec 17, 2015
Bull elephants exhibit marked increases in testosterone secretion during musth, and studies have shown a heightened sensitivity of the testis to GnRH-stimulated testosterone production in musth compared to nonmusth males. However, activity of the hyp...
Testosterone Gonadotropin-Releasing Hormone Luteinizing Hormone Drug Administration Schedule Sexual Behavior, Animal Animals Elephants Male
View on PubMed DOI

Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.

Pain medicine (Malden, Mass.) Dec 14, 2015
OBJECTIVES: A once-daily, extended-release hydrocodone bitartrate tablet with abuse-deterrent properties (Hysingla ER® [HYD]) is available for the treatment of chronic pain in appropriate patients. This study evaluated the intranasal abuse potential ...
Adult Male Middle Aged Double-Blind Method Analgesics, Opioid Humans Female Young Adult Delayed-Action Preparations Administration, Intranasal Hydrocodone Opioid-Related Disorders Cross-Over Studies Powders Illicit Drugs Drug Administration Schedule
View on PubMed DOI

Population pharmacokinetic/pharmacodynamic assessment of pharmacological effect of a selective estrogen receptor β agonist on total testosterone in healthy men.

Clinical pharmacology in drug development Jun 8, 2015
BACKGROUND: LY500307 is a highly selective estrogen receptor β (ERβ) agonist, which loses its selectivity at high dose and leads to undesirable suppression of total testosterone (TT) concentration. The objective of the present analysis was to define ...
Humans Biomarkers Young Adult Adult Benzopyrans Circadian Rhythm Drug Administration Schedule Administration, Oral Male Estrogen Receptor beta Cross-Over Studies Selective Estrogen Receptor Modulators Middle Aged Fourier Analysis Healthy Volunteers Testosterone London Nonlinear Dynamics Single-Blind Method Models, Biological
View on PubMed DOI

Revisiting Warfarin Dosing Using Machine Learning Techniques.

Computational and mathematical methods in medicine Jun 4, 2015
Determining the appropriate dosage of warfarin is an important yet challenging task. Several prediction models have been proposed to estimate a therapeutic dose for patients. The models are either clinical models which contain clinical and demographi...
Regression Analysis Anticoagulants Warfarin Drug Administration Schedule False Positive Reactions Reproducibility of Results Male Pharmacogenetics Genotype Dose-Response Relationship, Drug Humans Machine Learning Algorithms Databases, Factual Female
View on PubMed DOI

Pharmacokinetics of single and repeat doses of icatibant.

Clinical pharmacology in drug development Feb 2, 2015
PURPOSE: Icatibant is a bradykinin-2 receptor antagonist approved to treat acute hereditary angioedema attacks in adults. To-date, no thorough investigation of the clinical pharmacokinetic (PK) parameters of icatibant and its primary metabolites has ...
Bradykinin Bradykinin B2 Receptor Antagonists Models, Biological Healthy Volunteers Half-Life Drug Administration Schedule Metabolic Clearance Rate Middle Aged Adolescent Injections, Subcutaneous Anti-Inflammatory Agents, Non-Steroidal Area Under Curve Humans Female Young Adult Adult Male
View on PubMed DOI

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.

Clinical pharmacology in drug development Jan 26, 2015
PURPOSE: Rucaparib is a potent Poly (ADP-ribose) Polymerase (PARP) inhibitor currently under clinical development. The objectives of this analysis were to establish population PK and PK/PD models for rucaparib, and to evaluate the predictability of P...
Poly(ADP-ribose) Polymerases Poly(ADP-ribose) Polymerase Inhibitors Humans Biomarkers Computer Simulation Neoplasms Infusions, Intravenous Models, Biological Lymphocytes Indoles Drug Administration Schedule
View on PubMed DOI

Integrating real-world data and machine learning: A framework to assess covariate importance in real-world use of alternative intravenous dosing regimens for atezolizumab.

Clinical and translational science Nov 1, 2024
The increase in the availability of real-world data (RWD), in combination with advances in machine learning (ML) methods, provides a unique opportunity for the integration of the two to explore complex clinical pharmacology questions. Here we present...
Humans Middle Aged Antibodies, Monoclonal, Humanized Dose-Response Relationship, Drug Infusions, Intravenous Machine Learning Drug Administration Schedule Algorithms Administration, Intravenous Female Aged Male
View on PubMed DOI
Popular Topics
Recent Journals